相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
Eirini Panoilia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study
Andrea Warman et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2015)
Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases
Maria A. V. Willrich et al.
TRANSLATIONAL RESEARCH (2015)
Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects
C. L. M. Krieckaert et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Key findings towards optimising adalimumab treatment: the concentration-effect curve
Mieke F. Pouw et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
B. G. Levesque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Xavier Roblin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Towards an individualised target concentration of adalimumab in rheumatoid arthritis
Emilie Ducourau et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
Erik H. Vogelzang et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Optimizing Dosing of Oncology Drugs
L. Minasian et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Exposure-Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer
J. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis
Herbert Struemper et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Microfluidic platforms for biomarker analysis
Sofia Nahavandi et al.
LAB ON A CHIP (2014)
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL
E. Gibiansky et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study
Paul L. A. M. Corstjens et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2013)
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
Bart J. F. van den Bemt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease
Yi-Lin Chiu et al.
INFLAMMATORY BOWEL DISEASES (2013)
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2013)
The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
Jun Yang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Josee Golay et al.
MABS (2013)
Acquired resistance to drugs targeting receptor tyrosine kinases
Steven A. Rosenzweig
BIOCHEMICAL PHARMACOLOGY (2012)
A Guide to Rational Dosing of Monoclonal Antibodies
Shuang Bai et al.
CLINICAL PHARMACOKINETICS (2012)
Monoclonal antibody therapeutics: history and future
Nicholas A. P. S. Buss et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
Bo Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Gustavo Ismael et al.
LANCET ONCOLOGY (2012)
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
P. Mark Hogarth et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia
William G. Wierda et al.
CANCER (2011)
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
Nicolas Azzopardi et al.
CLINICAL CANCER RESEARCH (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load
Thijs H. Oude Munnink et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Diane D. Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Denis Mulleman et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Monoclonal antibodies in cancer therapy: 25 years of progress
Robert K. Oldham et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Pharmacokinetics of alemtuzumab and the relevance in clinical practice
Thomas Elter et al.
LEUKEMIA & LYMPHOMA (2008)
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
Mahboob U. Rahman et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing
Paula M. Fracasso et al.
CLINICAL CANCER RESEARCH (2007)
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath (R)) in patients with chronic lymphocytic leukaemia and its link to treatment response
D. R. Mould et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis
Chee M. Ng et al.
PHARMACEUTICAL RESEARCH (2006)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
G Hale et al.
BLOOD (2004)
Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
K Tobinai et al.
ANNALS OF ONCOLOGY (2004)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
T Igarashi et al.
ANNALS OF ONCOLOGY (2002)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
